Nykode Therapeutics

VACC

NO0010714785

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 08:15:00 08/05/2024 pm IST			5-day change	1st Jan Change
13.61 ^NOK	0.00%		+1.80%	-36.40%

19/04	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
19/04	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

October 27, 2023 at 07:47 pm IST

Oslo, Norway, October 27, 2023 - Primary insider Martin Nicklasson, Chair of the
Board of Nykode Therapeutics ASA, has today acquired 20,000 shares in Nykode
Therapeutics AS at a price of NOK 16.36 per share. Following the transaction,
Martin Nicklasson holds 52,000 shares in Nykode Therapeutics ASA. 
 
Please see further details in the attached document.

Click here for more information

Latest news about Nykode Therapeutics

Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	19/04	MT
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04	CI
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03	CI
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03	CI
Transcript : Nykode Therapeutics AS, Q4 2023 Earnings Call, Feb 28, 2024	28/02
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Transcript : Nykode Therapeutics AS Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	11/01
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12	CI
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
Transcript : Nykode Therapeutics AS, Q3 2023 Earnings Call, Nov 15, 2023	15/11
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	25/23/25	CI
Nykode Therapeutics AS announced that it expects to receive NOK 329.999987 million in funding	24/23/24	CI
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	29/23/29	MT
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	29/23/29	CI
Transcript : Nykode Therapeutics AS - Analyst/Investor Day	20/23/20
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	20/23/20	CI
Nykode Therapeutics Wins US FDA Nod for Mid-stage Study of Cervical Cancer Combo	05/23/05	MT
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	05/23/05	CI
Transcript : Nykode Therapeutics AS, Q2 2023 Earnings Call, Aug 23, 2023	23/23/23
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/23/23	CI
Nykode Adds New Cancer Vaccine Candidate in Clinical Trial Tie-up With Roche	01/23/01	MT
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer	01/23/01	CI
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Transcript : Nykode Therapeutics AS, Q1 2023 Earnings Call, May 12, 2023	12/23/12

Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nykode Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.61 NOK

Average target price

43 NOK

Spread / Average Target

+215.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NYKODE THERAPEUTICS	-36.40%	422M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.60%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-8.83%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.86B
VIKING THERAPEUTICS, INC.	+329.39%	8.78B

Bio Therapeutic Drugs